Dyno Therapeutics
Data as of .
Company facts
-
Founded
2018
-
Headquarters
United States (Watertown, MA)
-
Total funding
$109M
Latest funding round
- Round
- Series A
- Date
- May 2021
- Amount
- $100M
- Lead investor
- Andreessen Horowitz
Drug discovery partners
2 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Astellas Pharma
Option exercise (capsid license),
$15M upfront
-
Roche Pharma
Option exercise,
Terms not disclosed
Big tech ties
Not counted as pharma partners.
-
NVIDIA
Launched Psi-Phi suite at NVIDIA GTC,
Recent news
-
To present new capsids and AI work at ASGCT 2026
-
Astellas exercised option to license AI-designed muscle AAV capsid
-
Astellas exercised a $15M option to license a Dyno AI-designed AAV capsid for skeletal muscle gene delivery
-
Launches Dyno Psi-Phi, an agentic AI suite for protein binder design, at NVIDIA GTC
-
Launches Dyno-yp2, a brain-targeting AAV vector
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.